HR 3866 RFS 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Anabolic Steroid Con-
trol Act of 2004’’. 
SEC. 2. INCREASED PENALTIES FOR ANABOLIC STEROID 
OFFENSES NEAR SPORTS FACILITIES. 
(a) IN GENERAL.—Part D of the Controlled Sub-
stances Act is amended by adding at the end the following: 
ANABOLIC STEROID OFFENSES NEAR SPORTS FACILITIES 
‘‘SEC. 424. (a) Whoever violates section 401(a)(1) or 
section 416 by manufacturing, distributing, or possessing 
with intent to distribute, an anabolic steroid near or at 
a sports facility is subject to twice the maximum term of 
imprisonment, maximum fine, and maximum term of su-
pervised release otherwise provided by section 401 for that 
offense. 
‘‘(b) As used in this section—
‘‘(1) the term ‘sports facility’ means real prop-
erty where athletic sports or athletic training takes 
place, if such property is privately owned for com-
mercial purposes or if such property is publicly 
owned, but does not include any real property de-
scribed in section 419; 
‘‘(2) the term ‘near or at’ means in or on, or 
within 1000 feet of; and
HR 3866 RFS 
‘‘(3) the term ‘possessing with intent to dis-
tribute’ means possessing with the intent to dis-
tribute near or at a sports facility.’’. 
(b) TABLE OF CONTENTS AMENDMENT.—The table 
of contents for Comprehensive Drug Abuse Prevention 
and Control Act of 1970 is amended by inserting after 
the item relating to section 423 the following new item:
‘‘Sec. 424. Anabolic steroid offenses near sports facilities.’’.
SEC. 3. SENTENCING COMMISSION GUIDELINES. 
The United States Sentencing Commission shall—
(1) review the Federal sentencing guidelines 
with respect to offenses involving anabolic steroids; 
(2) consider amending the Federal sentencing 
guidelines to provide for increased penalties with re-
spect to offenses involving anabolic steroids in a 
manner that reflects the seriousness of such offenses 
and the need to deter anabolic steroid use; and 
(3) take such other action that the Commission 
considers necessary to carry out this section. 
SEC. 4. AMENDMENTS TO THE CONTROLLED SUBSTANCES 
ACT. 
(a) DEFINITIONS.—Section 102 of the Controlled 
Substances Act (21 U.S.C. 802) is amended—
(1) in paragraph (41)—
(A) by realigning the margin so as to align 
with paragraph (40); and
HR 3866 RFS 
(B) by striking subparagraph (A) and in-
serting the following: 
‘‘(A) The term ‘anabolic steroid’ means any drug or 
hormonal substance, chemically and pharmacologically re-
lated to testosterone (other than estrogens, progestins, 
corticosteroids, and dehydroepiandrosterone), and in-
cludes—
‘‘(i) androstanediol—
‘‘(I) 3β,17β-dihydroxy-5α-androstane; and 
‘‘(II) 3α,17β-dihydroxy-5α-androstane; 
‘‘(ii) 
androstanedione 
(5α-androstan-3,17-
dione); 
‘‘(iii) androstenediol—
‘‘(I) 1-androstenediol (3β,17β-dihydroxy-
5α-androst-1-ene); 
‘‘(II) 1-androstenediol (3α,17β-dihydroxy-
5α-androst-1-ene); 
‘‘(III) 4-androstenediol (3β,17β-dihydroxy-
androst-4-ene); and 
‘‘(IV) 5-androstenediol (3β,17β-dihydroxy-
androst-5-ene); 
‘‘(iv) androstenedione—
‘‘(I) 1-androstenedione ([5α]-androst-1-en-
3,17-dione);
HR 3866 RFS 
‘‘(II) 
4-androstenedione 
(androst-4-en-
3,17-dione); and 
‘‘(III) 
5-androstenedione 
(androst-5-en-
3,17-dione);
‘‘(v) 
bolasterone 
(7α,17α-dimethyl-17β-
hydroxyandrost-4-en-3-one); 
‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene-
3-one); 
‘‘(vii) 
calusterone 
(7β,17α-dimethyl-17β-
hydroxyandrost-4-en-3-one); 
‘‘(viii) clostebol (4-chloro-17β-hydroxyandrost-4-
en-3-one); 
‘‘(ix) dehydrochlormethyltestosterone (4-chloro-
17β-hydroxy-17α-methylandrost-1,4-dien-3-one); 
‘‘(x) ∆1-dihydrotestosterone (also known as 1-
testosterone) (17β-hydroxy-5α-androst-1-en-3-one); 
‘‘(xi) 
4-dihydrotestosterone 
(17β-hydroxy-
androstan-3-one); 
‘‘(xii) drostanolone (17β-hydroxy-2α-methyl-5α-
androstan-3-one); 
‘‘(xiii) ethylestrenol (17α-ethyl-17β-hydroxyestr-
4-ene); 
‘‘(xiv) fluoxymesterone (9-fluoro-17α-methyl-
11β,17β-dihydroxyandrost-4-en-3-one);
HR 3866 RFS 
‘‘(xv) 
formebolone 
(2-formyl-17α-methyl-
11α,17β-dihydroxyandrost-1,4-dien-3-one); 
‘‘(xvi) 
furazabol 
(17α-methyl-17β-
hydroxyandrostano[2,3-c]-furazan); 
‘‘(xvii) 13α-ethyl-17β-hydroxygon-4-en-3-one; 
‘‘(xviii) 4-hydroxytestosterone (4,17β-dihydroxy-
androst-4-en-3-one); 
‘‘(xix) 
4-hydroxy-19-nortestosterone 
(4,17β-
dihydroxy-estr-4-en-3-one); 
‘‘(xx) mestanolone (17α-methyl-17β-hydroxy-
5α-androstan-3-one); 
‘‘(xxi) 
mesterolone 
(1α-methyl-17β-hydroxy-
[5α]-androstan-3-one); 
‘‘(xxii) 
methandienone 
(17α-methyl-17β-
hydroxyandrost-1,4-dien-3-one); 
‘‘(xxiii) 
methandriol 
(17α-methyl-3β,17β-
dihydroxyandrost-5-ene); 
‘‘(xxiv) methenolone (1-methyl-17β-hydroxy-5α-
androst-1-en-3-one); 
‘‘(xxv) 
methyltestosterone 
(17α-methyl-17β-
hydroxyandrost-4-en-3-one); 
‘‘(xxvi) 
mibolerone 
(7α,17α-dimethyl-17β-
hydroxyestr-4-en-3-one);
HR 3866 RFS 
‘‘(xxvii) 17α-methyl-∆1-dihydrotestosterone (17 
β-hydroxy-17α-methyl-5α-androst-1-en-3-one) (also 
known as ‘17-α-methyl-1-testosterone’); 
‘‘(xxviii) nandrolone (17β-hydroxyestr-4-en-3-
one); 
‘‘(xxix) norandrostenediol—
‘‘(I) 19-nor-4-androstenediol (3β, 17β-
dihydroxyestr-4-ene); 
‘‘(II) 19-nor-4-androstenediol (3α, 17β-
dihydroxyestr-4-ene); 
‘‘(III) 19-nor-5-androstenediol (3β, 17β-
dihydroxyestr-5-ene); and 
‘‘(IV) 19-nor-5-androstenediol (3α, 17β-
dihydroxyestr-5-ene); 
‘‘(xxx) norandrostenedione—
‘‘(I) 19-nor-4-androstenedione (estr-4-en-
3,17-dione); and 
‘‘(II) 19-nor-5-androstenedione (estr-5-en-
3,17-dione); 
‘‘(xxxi) 
norbolethone 
(13β,17α-diethyl-17β-
hydroxygon-4-en-3-one); 
‘‘(xxxii) norclostebol (4-chloro-17β-hydroxyestr-
4-en-3-one); 
‘‘(xxxiii) 
norethandrolone 
(17α-ethyl-17β-
hydroxyestr-4-en-3-one);
HR 3866 RFS 
(b) AUTHORITY
AND CRITERIA
FOR CLASSIFICA-
TION.—Section 201(g) of the Controlled Substances Act 
(21 U.S.C. 811(g)) is amended—
(1) in paragraph (1), by striking ‘‘substance 
from a schedule if such substance’’ and inserting 
‘‘drug which contains a controlled substance from 
the application of titles II and III of the Comprehen-
sive Drug Abuse Prevention and Control Act (21 
U.S.C. 802 et seq.) if such drug’’; and 
(2) in paragraph (3), by adding at the end the 
following: 
‘‘(C) Upon the recommendation of the Sec-
retary of Health and Human Services, a compound, 
mixture, or preparation which contains any anabolic 
steroid, which is intended for administration to a 
human being or an animal, and which, because of its 
concentration, preparation, formulation or delivery 
system, does not present any significant potential for 
abuse.’’. 
(c) ANABOLIC STEROIDS CONTROL ACT.—Section 
1903 of the Anabolic Steroids Control Act of 1990 (Public 
Law 101–647; 21 U.S.C. 802 note) is amended—
(1) by striking subsection (a); and 
(2) by redesignating subsections (b) and (c) as 
subsections (a) and (b), respectively.
HR 3866 RFS 
SEC. 5. REPORTING REQUIREMENT. 
Not later than 2 years after the date of the enact-
ment of this Act, the Secretary of Health and Human 
Services, in consultation with the Attorney General, shall 
prepare and submit a report to the Judiciary Committee 
of the House and Senate, and to the Committee on Energy 
and Commerce of the House, evaluating the health risks 
associated with dietary supplements not scheduled under 
the amendments made by this Act which contain sub-
stances similar to those added to the list of controlled sub-
stances under those amendments. The report shall include 
recommendations on whether such substances should be 
regulated as anabolic steroids.
Passed the House of Representatives June 3, 2004. 
Attest: 
JEFF TRANDAHL, 
Clerk.